Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry.

ABSTRACT:

Objectives

The CytoSorb therapy in COVID-19 (CTC) registry evaluated the clinical performance and treatment parameters of extracorporeal hemoadsorption integrated with veno-venous extracorporeal membrane oxygenation (VV ECMO) in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS) and respiratory failure under US FDA Emergency Use Authorization.

Design

Multicenter, observational, registry (NCT04391920).

Setting

Intensive care units (ICUs) in five major US academic centers between April 2020 and January 2022.

Patients

A total of 100 critically ill adults with COVID-19-related ARDS requiring VV ECMO support, who were treated with extracorporeal hemoadsorption.

Interventions

None.

Measurements and main results

Baseline dem

SUBMITTER: Hayanga JWA 

PROVIDER: S-EPMC10280833 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature